{"id":586101,"date":"2026-07-13T00:00:00","date_gmt":"2026-07-13T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreim0032-2026-biopharma-crohns-disease-access-reimbursement-access-reimbursement-crohns-disease-us\/"},"modified":"2026-07-13T00:00:00","modified_gmt":"2026-07-13T00:00:00","slug":"acreim0032-2026-biopharma-crohns-disease-access-reimbursement-access-reimbursement-crohns-disease-us","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreim0032-2026-biopharma-crohns-disease-access-reimbursement-access-reimbursement-crohns-disease-us\/","title":{"rendered":"Crohn&#8217;s Disease &#8211; Access &#038; Reimbursement &#8211; Access &#038; Reimbursement &#8211; Crohn&#8217;s Disease (US)"},"content":{"rendered":"<p><abbr data-abbreviation-entity=\"4976\" title=\"tumor necrosis factor\">TNF<\/abbr>-\u03b1 inhibitors, such as J&#038;J Innovative Medicine\u2019s Remicade and AbbVie\u2019s Humira, remain firmly established in the U.S. Crohn\u2019s disease (<abbr data-abbreviation-entity=\"4751\" title=\"Crohn's disease\">CD<\/abbr>) treatment landscape. However, therapies with alternative mechanisms of action\u2014including Takeda\u2019s Entyvio, J&#038;J Innovative Medicine\u2019s Stelara, and AbbVie\u2019s Skyrizi and Rinvoq\u2014along with recently launched agents such as Eli Lilly\u2019s Omvoh and J&#038;J Innovative Medicine\u2019s Tremfya, are gaining traction and reshaping treatment paradigms. In parallel, growing uptake of infliximab and adalimumab biosimilars will broaden therapeutic options. Furthermore, the introduction of ustekinumab biosimilars, including Wezlana and Selarsdi, together with the anticipated entry of emerging agents\u2014some featuring novel mechanisms of action, such as Merck\u2019s tulisokibart, Roche\u2019s afimkibart, Sanofi\/Teva\u2019s duvakitug, and J&#038;J Innovative Medicine\u2019s icotrokinra\u2014is expected to intensify competition and exert additional pricing pressure. This report examines market access challenges facing emerging therapies, offering insights into strategies for achieving favorable coverage and driving uptake.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>How do <abbr data-abbreviation-entity=\"4883\" title=\"managed care organization\">MCO<\/abbr> restrictions impact physicians\u2019 prescribing of biologics \/ oral targeted agents for <abbr data-abbreviation-entity=\"4751\" title=\"Crohn's disease\">CD<\/abbr>?<\/li>\n<li>How do <abbr data-abbreviation-entity=\"4883\" title=\"managed care organization\">MCO<\/abbr>s cover branded biologics \/ oral targeted agents in their largest fully insured commercial plans, and which utilization management controls do they use?<\/li>\n<li>How do pharmacoeconomic \/ health economic and outcomes research data impact formulary decision-making about therapies for <abbr data-abbreviation-entity=\"4751\" title=\"Crohn's disease\">CD<\/abbr>?<\/li>\n<li>How do payers expect to cover recently approved \/ emerging therapies, including Omvoh, Tremfya, tulisokibart, afimkibart, duvakitug, and icotrokinra, in their commercial health plans, and how does this coverage align with physicians\u2019 anticipated prescribing of these agents?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Leveraging Clarivate\u2019s proprietary data sources and surveys with physicians and payers, Access &#038; Reimbursement provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of payer policy on physician prescribing behavior in the United States. Through detailed analyses of drug coverage, restriction policies, and contracting, as well as payer and prescriber perspectives on key marketed drugs and their receptivity to emerging therapies, this report enables you to:<\/p>\n<ul class=\"BulletListStyle1 SCXW92978545 BCX8 round-bullets\">\n<li>Identify and learn how to overcome roadblocks to market access to best position your brand.<\/li>\n<li>Identify key stakeholders and reimbursement drivers and assess the impact that reimbursement decisions have on treatment selection.<\/li>\n<li>Evaluate competitor strategies for securing favorable market access terms.<\/li>\n<\/ul>\n<p><b>Geography: <\/b>United States<\/p>\n<p><strong>Primary research:<\/strong> Survey of 100 U.S. gastroenterologists and 30 U.S. managed care organization (<abbr title=\"managed care organization\">MCO<\/abbr>) pharmacy and medical directors (<abbr title=\"pharmacy director\">PD<\/abbr>s\/<abbr title=\"medical director\">MD<\/abbr>s). Interviews with 2 U.S. <abbr data-abbreviation-entity=\"4883\" title=\"managed care organization\">MCO<\/abbr> <abbr data-abbreviation-entity=\"5531\" title=\"pharmacy director\">PD<\/abbr>s\/<abbr data-abbreviation-entity=\"4885\" title=\"medical director\">MD<\/abbr>s.<\/p>\n<p><strong>Fingertip Formulary: <\/strong>Formulary coverage by commercial plans covering more than 163 million lives nationally.<\/p>\n<p><strong>Real-world data:<\/strong> U.S. pharmacy and medical claims data<\/p>\n<p><strong>Key drugs<\/strong>: Remicade, Humira, biosimilar adalimumab, biosimilar infliximab, Entyvio, Stelara, biosimilar ustekinumab, Rinvoq, Skyrizi, Tremfya, Omvoh.<\/p>\n","protected":false},"template":"","class_list":["post-586101","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-crohns-disease","biopharma-therapy-areas-gastrointestinal","biopharma-geography-us","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/586101","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=586101"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}